Skip to content Skip to footer
Subscribe Now
NEWS

Merz Therapeutics Enrolls First Patients in P-III Studies Evaluating Xeomin for Migraine Prevention

Shots: Merz Therapeutics has enrolled the first patients in two global P-III studies, MINT-E (episodic migraine, ~990 pts) and MINT-C (chronic migraine, ~780 pts), evaluating the efficacy and safety of Xeomin (incobotulinumtoxinA) for migraine prevention Both studies will recruit ~1,770 adults across 120 sites in North America & Europe, and recruitment in Europe is expected…
6 hours ago

Read more

NEWS

Teva Reports the Data from the P-IV (PEARL) Study of Ajovy (fremanezumab) for Chronic and Episodic Migraine Prevention

S Shots: The P-IV (PEARL) study (N=1140) evaluating fremanezumab met its 1EP and 2EPs, demonstrating long-term effectiveness over two years, significantly reducing the frequency, duration, and severity of migraine attacks in both chronic and episodic migraine pts The study met 1EP of ≥50% reduction in MMD within the first 6mos. of treatment. Injection adherence remained high…
June 23, 2025

Read more

PharmaShots Interview Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Eric Pearlman Shares Insight on Emgality (galcanezumab-gnlm) for the Treatment of Episodic Migraine

In an interview with PharmaShots, Eric Pearlman, Associate Vice President, Global & US Medical Affairs at Eli Lilly shared his views on the initiation of the patients enrollment in P-IV (CHALLENGE-MIG) head-to-head trial of Emgality for episodic migraine in adults Shots: The company initiate the patients' enrollment for the P-IV (CHALLENGE-MIG) head-to-head trial to evaluate the efficacy and safety of Emgality vs Nurtec ODT…
March 29, 2022

Read more